肾移植受者心房颤动:新型药物是否有用武之地?
本文综述肾移植受者心房颤动的流行病学、临床后果与抗凝治疗现状。房颤在移植后3年内发生率超过7%,与缺血性卒中、移植物失败和死亡风险升高相关。目前缺乏随机研究和专门指南,新型口服抗凝药和左心耳封堵术可能成为治疗选择。
要点
- 肾移植受者房颤发生率在移植后3年内超过7%,与移植物失败和死亡风险升高相关。
- 该人群缺乏随机研究和专门指南,口服抗凝治疗决策需个体化。
- 新型口服抗凝药经肾排泄且可能与免疫抑制剂相互作用,需遵循产品说明书使用。
核心结论
- 肾移植受者房颤与缺血性卒中、移植物失败和移植后死亡风险升高相关。
- 新型口服抗凝药在该人群中有应用价值,但需遵循产品说明书并关注肾功能与免疫抑制剂相互作用。
- 左心耳封堵术可考虑用于存在抗凝禁忌的肾移植受者。
研究设计与样本
- 综述性文章,总结肾移植受者心房颤动的流行病学、临床后果与抗凝治疗证据。
主要发现
- 房颤在一般人群发生率为2%,在慢性肾脏病患者中为19-24%。
- 肾移植受者移植后3年内房颤发生率超过7%,与移植物和患者生存率降低相关。
- 肾移植后卒中发生率高于一般人群,但明显低于透析患者。
- 有房颤史的肾移植受者缺血性卒中、移植物失败和移植后死亡率显著更高。
关键数值与推荐
- 口服抗凝治疗推荐用于卒中高风险的房颤患者。
- 目前无随机研究评估肾移植受者的口服抗凝治疗,也无专门指南推荐。
- 新型口服抗凝药至少与华法林同样有效,且更安全,尤其减少颅内出血。
临床怎么用
- 肾移植受者房颤抗凝决策应个体化,评估卒中与出血风险。
- 使用新型口服抗凝药需遵循产品说明书,关注肾功能和免疫抑制剂相互作用。
- 存在抗凝禁忌时可考虑左心耳封堵术。
局限性
- 缺乏肾移植受者口服抗凝治疗的随机研究。
- 无针对该人群的专门指南或推荐。
- 新型口服抗凝药在该人群中应用不足,医生经验有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia of high clinical importance, occurring in 2% of the general population and in 19-24% in patients with chronic kidney disease. It is a well-known risk factor for cardiovascular morbidity and mortality. Kidney transplant recipients with a history of AF were associated with significantly higher rate of ischaemic strokes, graft failure and post-transplant mortality. AF occurs in over 7% of kidney transplant recipients in the first 3 years after transplantation and is associated with reduced graft and patient survival. The incidence of stroke in patients after kidney transplantation (KTx) is higher than the general population, but markedly lower than those on dialysis. Oral anticoagulation (OAC) therapy is recommended in AF patients at high risk of stroke. There are no randomized studies assessing OAC in patients after KTx and there are no specific recommendations and guidelines on therapeutic strategies in these patients. KTx recipients are a vulnerable population, exposed to variations in renal function, being at higher risk of bleeding and thrombotic complications, with possible interactions with immunosuppression. Surely, there is a place for novel oral anticoagulants (NOACs) in this group of patients as long as the summary of product characteristics is followed, as they are a valuable anticoagulation therapy. On one hand, they are at least as effective as warfarin; on the other hand NOACs are safer, especially when it comes to intracranial haemorrhages. However, NOACs seem to be underused in this population as they are excreted via kidney, may interact with immunosuppressive therapy and physicians need more experience and confidence in their administration. Percutaneous left atrial appendage occlusion procedure may also be considered as an opportunity for this group of patients, in particular in the presence of contraindications to anticoagulation.
引用
- Malyszko J, Lopatowska P, Mlodawska E, et al. Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs? Nephrol Dial Transplant. 2018. PMID: 28992319. doi:10.1093/ndt/gfx265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。